<DOC>
	<DOCNO>NCT00852176</DOCNO>
	<brief_summary>The study evaluate long-term safety efficacy intravascular beta radiation therapy treat coronary in-stent restenosis use Beta-Cath ( TM ) 3.5F System ; data collect retrospectively patient treat Beta-Cath™ 3.5F System routine clinical practice follow FDA pre-market approval System . Outcomes report 5 year follow treatment .</brief_summary>
	<brief_title>Retrospective Long-term Safety Efficacy Study Beta-Cath ( TM ) 3.5F System</brief_title>
	<detailed_description />
	<criteria>Patients underwent onlabel treatment ( define ) BetaCath™ 3.5F System ( 30 , 40 60mm ) instent restenosis ( ISR ) coronary stenting . 1 . Onlabel treatment 30 40mm BetaCath™ 3.5F System define : treatment ISR native coronary artery discrete lesion ( treatable 20mm balloon ) reference vessel diameter ( RVD ) range 2.7mm 4.0mm 2 . Onlabel treatment 60mm BetaCath™ 3.5F System define : treatment ISR native coronary artery lesion &lt; 40mm length RVD range 2.7mm 4.0mm Patients must undergo brachytherapy treatment least 68 month prior enrollment retrospective study date treatment must : 1 . On February 8 , 2002 30/40mm 3.5F System 2 . On June 25 , 2003 60mm 3.5F System Patients give informed consent Patients meet inclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Coronary brachytherapy</keyword>
	<keyword>Coronary restenosis</keyword>
	<keyword>Coronary stent restenosis</keyword>
</DOC>